Agenus Inc. has completed the closing of its previously announced strategic collaboration with Zydus Lifesciences Ltd., a move aimed at accelerating the global development and potential commercialization of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination. The agreement strengthens Agenus’s financial position while securing long-term biologics manufacturing capacity in the United States to support clinical development, early access programs, and future commercial supply.
The collaboration, first disclosed in June 2025, provides Agenus with strategic capital and dedicated U.S.-based manufacturing infrastructure at a critical stage in the advancement of its immuno-oncology pipeline. As part of the deal, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. In return, Agenus will be eligible to receive royalties on net sales in those markets.
Financially, the transaction includes a $75 million upfront cash payment to Agenus related to the transfer of its biologics manufacturing facilities in Emeryville and Berkeley, California. Zydus has also made a $16 million equity investment in Agenus through the purchase of approximately 2.1 million common shares at $7.50 per share. In addition, the agreement includes contingent milestone payments of up to $50 million, tied to future BOT+BAL production orders, and a 5% royalty on net sales in India and Sri Lanka.
Following the closing, the California manufacturing facilities will be transferred to Zydus and operated under a newly formed subsidiary, Zylidac Bio LLC. Despite the transfer, Agenus has secured committed manufacturing capacity at these sites to support its ongoing clinical trials, global access initiatives, and future commercialization efforts for BOT+BAL.
Agenus’s BOT+BAL program has generated encouraging clinical data in microsatellite-stable metastatic colorectal cancer, a population with limited treatment options. In 2025, the combination demonstrated a two-year overall survival rate of 42% and a median overall survival of 21 months in an expanded cohort of heavily pretreated patients without active liver metastases. Building on these results, Agenus and the Canadian Cancer Trials Group have launched the global BATTMAN Phase 3 trial, which is now activating sites and preparing to enroll patients.
Company executives said the collaboration positions Agenus to focus on disciplined execution in 2026, including advancing Phase 3 development, expanding paid patient access through authorized pathways, and moving toward regulatory submission. For Zydus, the transaction expands its U.S. biologics manufacturing footprint and supports the growing demand for secure, high-quality domestic supply chains for advanced therapies.